|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Reporting Guidelines for Susceptibility Reporting | | | | | | | | |
| **Policy Statement** | The decisions for the most appropriate antimicrobial agents to test and report are made with input from Pharmacy, Infectious Disease and the Clinical Laboratory. The goal is to provide clinically relevant information that will support cost-effective utilization of antimicrobial agents and to avoid reporting results that could adversely affect patient care. | | | | | | | |
| **Purpose** | This policy documents and provides guidance for the processes and procedures for routine testing and reporting of Antimicrobial Agents / organism groupings | | | | | | | |
| **Responsibility** | Microbiologists who perform and result antimicrobial susceptibilities | | | | | | | |
| *Enterobacteriaceae*  Vitek AST 69 or 79 or  MSCN NC32 MIC or  KBS disk diffusion  (Reported for urine \*\*) | Pseudomonas aeruginosa or  other non-Enterobacteriaceae  Vitek AST 69 or 79 or  MSCN-- NC32 MIC or  **KBS disk diffusion**  **(Reported for urine \*\*)** | | ***Steno. maltophilia***  **MSCN--NC32 MIC** | ***Bacillus sp.***  **Refer AST**  **U of M** | | | *Salmonella*  *Shigella*  **KB GN/Urine for *Salmonella***  **Vitek AST 69 for *Shigella*** | |
| -Ampicillin\*\*  -Amikacin  -Amoxicillin/Clavulanate\*\*  -Amp/Sulbactam\*\*  -Cefazolin\*\*  -Ceftazidime\*\*  -Ceftriaxone\*\*  -Ciprofloxacin\*\*  -Gentamicin\*\*  -Imipenem  Piperacillin/Tazobactam\*\*  -Tobramycin\*\*  -Trimethoprim/Sulfa\*\*  -Meropenem  -Cefepime\*\*  -Nitrofurantoin (urine only) | -Amikacin\*\*  --Aztreonam\*\*  -Ceftazidime\*\*  -Gentamicin\*\*  -Ciprofloxacin\*\*  -Imipenem\*\*  -Meropenem  -Cefepime\*\*  -Piperacillin/Tazobactam  (pip/tazo)\*\*  -Tobramycin\*\* | | -Trimethoprim/Sulfa  -Ceftazidime  -Levofloxacin  . |  | | | -Ampicillin  -Ciprofloxacin  -Trimethoprim/Sulfa  *Salmonella spp*. only  -Ceftriaxone  extraintestinal sources only  -Chloramphenicol  Extraintestinal isolates if requested. | |
| **CF cultures**  **Non-fermenters--**  **gram neg bacilli**  **Vitek AST 79 or**  **MSCN—NC32 MIC or**  **KBS disk diffusion**  **\*\*Mucoid neg rods**  **(KBS only for AST)**  -Amikacin  -Ceftazidime  -Gentamicin  -Ciprofloxacin  -Imipenem  -Meropenem  -Cefepime  -Piperacillin/Tazobactam  -Tobramycin  -Aztreonam--\*\*\***KBS for PSAR** | **CF cultures**  ***Staph aureus*—**  **Small colony variant**  **KBS disk diffusion**  **MH with SB in CO2**  -Clindamycin  -Erythromycin  -Gentamicin  -Oxacillin  -Penicillin  -Rifampin  -Trimethoprim/Sulfa  -ICR  (Inducible Clindamycin resistance)  **ETEST**  **-**Vancomycin | | ***B. cepacia***  Vitek AST 69 or 79  (and for confirmation)  MSCN-- NC32 MIC  -Trimethoprim/Sulfa  -Ceftazidime  -Levofloxacin  -Meropenem | ***N. meningitidis***  **DO ALL PROCEDURES IN BSC**  **KBS disk diffusion MH with SB in CO2**  Perform BL test  -Trimethoprim/Sulfa  -Ceftriaxone  -Ciprofloxacin  -Meropenem  -Rifampin  -Nalidixic acid (leave in “HIDE”)  Neisseria that test R to NA may be associated with clinical failure.  **(If NA = R,**  **report CP as R)** | | | ***Aeromonas***  **(Stool)**  **Vitek AST 69**  -Ciprofloxacin  -Trimethoprim/Sulfa  -Ceftriaxone | |
| *Staphylococcus* sp.  *Listeria* (MSCN- PC20)  Vitek AST 67 or  MSCN PC20 or  KBS disk diffusion  (Reported for urine \*\*)  (Reported for *Listeria\*\*)*  Add comment:  If: OX SS🡪 STPH1  If: OX R🡪 STPH2 | ***Enterococcus* sp.**  Vitek AST 67 or  MSCN PC20 or  **KBS disk diffusion**  **(Reported for urine \*\*)** | | ***Strep. pneumoniae***  Vitek AST 74 or  MSTRP or  **KBS disk diffusion**  **& Penicillin Etest**  **(Reported for CSF and Blood isolates\*\*)** | ***Streptococcus* sp. {αlpha or βeta}**  **(not ES or SPNE)**  **αlpha-strep🡪MSTRP**  **(or KBS disk MHSB)**  **β-strep Group A🡪MSTRP**  **(or KBS disk diffusion**  **on MH with SB in CO2)**  **(ONLY done per special request; i.e. penicillin allergy)**  **β-strep Group B🡪**  **Vitek-67 card or PC20** | | | | ***Haemophilus* sp.**  **HTM🡪KBS disk diffusion**  **in CO2**  --Perform BL testing  **(Reported for CSF isolates)**  **\*\*** |
| -Ciprofloxacin\*\*  -Clindamycin  -Erythromycin  -Gentamicin\*\*  -Oxacillin\*\*  -Penicillin\*\*\*\*-**hide if susceptible**  -Rifampin  -Trimethoprim/Sulfa\*\*  -Vancomycin  -Nitrofurantoin (urine only)  -ICR  (Inducible Clindamycin resistance)  --Ampicillin\*\*(*Listeria only)* | -Ampicillin\*\*  -Vancomycin  -Ciprofloxacin  (Urine only)\*\*  -Nitrofurantoin  (Urine only)\*\*  -Gent Synergy - Screen  (Systemic infections only) | | -Penicillin\*\*  -Cefotaxime\*\*  -Ceftriaxone\*\*  -Erythromycin  -Clindamycin  -Trimethoprim/Sulfa  -Vancomycin\* \*  (Reported only if other drugs are resistant)  -Meropenem\*\*  -Chloramphenicol\*\*  (Reported only if other drugs are resistant) | -Ampicillin  -Penicillin  -Cefotaxime  -Ceftriaxone  -Erythromycin\*\*  -Clindamycin\*\*  -Vancomycin  -Chloramphenicol  -Cefepime (SVIR/AHS)  -Levofloxacin(SVIR/AHS)  **[DO NOT REPORT: Chloro / Erythro / Clinda on URINE isolates]**  -Perform ICR for β-strep  (Inducible Clindamycin resistance)  (\*\*not on neonates) | | | | -Ampicillin\*\*  -Augmentin  -Ciprofloxacin  -Cefotaxime\*\*  -Ceftriaxone\*\*  -Trimethoprim/Sulfa  -Meropenem\*\* |
| ***Lactobacillus* sp.**  **Refer AST**  **U of M** |  | |  |  | | | |  |
| -Penicillin  -Vancomycin  -Erythromycin  -Clindamycin |  | |  |  | | | |  |
| Supplemental or Confirmatory Testing |  | |  | | | | | |
| **Inducible Clindamycin Resistance -- ICR** | | This is performed on the Vitek AST 67 card for all *Staphylococci.* If the ICR is positive the Clindamycin MIC is reported as ≥8.  Disk diffusion D-testing is also available for SCV *Staph aureus,* andβ- hemolytic strep. Place the E and CC disks 15-26 mm apart for Staph;  For β- hemolytic strep, place disks 12 mm apart. | | | | | |
| **Deduced Cefazolin** | | Cefazolin (1st generation cephalosporin) is a deduced result on Vitek GP67 cards. Report in Sunquest as “SS” or “R” in the additional susceptibility results pop-up box, or in the susceptibility tab. **Do not report for CSF**. | | | | | |
| **Cefoxitin Disk Screen for MRSA** | | This is performed on Staphylococcus aureus isolates that do not need complete susceptibility test panels.  FOX zone of ≥ 22mm: report as: SS --MSSA  FOX zone of ≤ 21mm: report as: R --MRSA | | | | | |
| **Penicillin Etest for**  ***St. pneumoniae*** | | Per the package inserts for Etest strips, please round UP to the next doubling dilution.  Enter Etest reading in the Sunquest culture work-up along with “reported as \_\_\_\_\_”.  Report in Sunquest Susceptibility tab, resulting **PENNM**, **PENM**, **PENV,** with the same result (do not release the Vitek 74 online result for P).  **DO NOT REPORT PENV (oral) on sterile body sites; i.e. CSF, BC, or BF.**  readings of .002 thru .047 are reported as **<=0.06**  readings of .064 and .094 are reported as **0.12**  readings of .125 and .25 are reported as **0.25**  readings of .38 and .5 are reported as **0.5**  readings of .75 and 1.0 are reported as **1**  readings of 1.5 and 2 are reported as **2**  readings of 3 and 4 are reported as **4**  readings 6 or greater are reported as **>=8** | | | | | |
| **ESBL detection** | | This is performed on Vitek AST 69 or 79 cards for *E. coli, K. pneumoniae, K. oxytoca.*  If Vitek AES phenotype is ESBL or ESBL (CTX-M LIKE), report the ESBL as positive.  For *Proteus mirabilis:* Perform phenotypic disk confirmatory test if the Vitek AES reports an ESBL phenotype. | | | | | |
| **KPC detection** | | Perform Vitek AST 69 or 79. If Vitek AES phenotype is a possible Carbapenemase producer, send to MDH Project 1380, using the Clinical Isolate Submission Form. **If MDH results are positive for Carbapenemase Producer, change all carbapenems drugs to resistant.** If Negative, report as tested. | | | | | |
| **Enterococcus--HLAR** | | High-Level Aminoglycoside resistance (HLAR) is tested with the Vitek AST 67 card and the MSCN PC-20 panel. Gentamycin synergy (GMSS) is reported on systemic enterococcal isolates. If Gent synergy is SSR, confirm the result with MSCN. | | | | | |
| **Enterococcus--VRE** | | If the Vancomycin MIC is =8 μg/ml or higher, confirm with Etest vanco strip, set up Vitek GPI for identification and perform testing for motility and pigment production to distinguish species with acquired resistance (*vanA* and *vanB* from those with intrinsic, intermediate level resistance to vancomycin such as *E.gallinarum* and *E.casseliflavus*. | | | | | |
| **Supplemental Antimicrobial Agents** | | If additional susceptibility testing is requested and cannot be performed in our lab the test is sent to UM Fairview Medical Center. Refer to [MCVI 5.2 Micro Send-out Reporting](file:///G:\Lab%20Procedures\Microbiology\1NEW%20Micro%20Procedure%20Manual.%20(same%20as%20in%20Starnet)\MCVI%205%20Computer\MCVI%205.2%20Micro%20Sendout%20Resulting.docx) Procedure for additional information. | | | | | |
| Misleading Results | **Do not report the following:** | | *Salmonella and Shigella*: first and second generation cephalosporins and aminoglycosides  Staph sp.: do not report CF; AM; AMC-- the beta-lactam drugs—(except Penicillin and Cefazolin)  ESBL-producing *E. coli, Proteus* sp., and *Klebsiella* sp.: cephalosporins, penicillins, and aztreonam  *Enterococcus* sp.: cephalosporins, trimeth/sulfa, clindamycin, and aminoglycosides  *Listeria:* Cephalosporins. *Listeria* is intrinsically resistant to cephalosporins | | | | | |
| CLSI CSF Reporting Rule | **“Warning”: The following antimicrobial agents should not be routinely reported for bacteria isolated from CSF.** | | --Agents administered by oral route only—Do not report Cefazolin  1st -and 2nd-generation cephalosporins (except Cefuroxime parenteral) and cephamycins  --Clindamycin  --Macrolides (Erythromycin)  --Tetracyclines  --Fluoroquinolones—e.g. Ciprofloxacin, and the other “floxacins" | | | | | |
| Inconsistent Antimicrobial Results | Inconsistent or unusual results must be confirmed. The Vitek AES, Advanced Expert System and the Bio-ART rules flag results from the Vitek cards. The Sunquest Susceptibility Quality Assurance rules will give a pop-up QA warning when entering inconsistent results that need to be confirmed. Do not accept these flagged results until verified. | | | | | | | |
| AST Frequency | Isolates that are initially susceptible may become intermediate or resistant after the initiation of therapy. Susceptibilities are repeated every three days if the same isolate is recovered from subsequent cultures.  Special requests for earlier repeat susceptibility testing may be warranted due to the severity of the patient’s condition. These will be determined after consultation with the medical staff and Infectious Disease physicians. | | | | | | | |
| References | 1. Hindler, J.F., Section editor, “Antimicrobial Susceptibility Testing” in *Clinical Microbiology Procedures Handbook,* Garcia, Lynne, editor, 2010, ASM Press, Washington, D.C. 2. CLSI. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-fifth Informational Supplement. CLSI document M100-25. Wayne, PA: Clinical Laboratory Standards Institute; 2015 | | | | | | | |
| **Training Plan/ Competency Assessment** | **Training Plan** | | | | **Initial Competency Assessment** | | | |
| * + 1. Employee must read the procedure     2. Employee will observe trainer performing the procedure.     3. Employee will demonstrate the ability to perform procedure, record results and document corrective action after instruction by the trainer. | | | | 1. Direct Observation. | | | |
| Historical Record | **Version** | **Written/ Revised by:** | | | **Effective Date:** | **Summary of Revisions** | | |
|  | 1.0 | Pat Ackerman | | | 5/1/1990 | Initial Version | | |
|  | 1.1 | Pat Ackerman | | | 9/16/2001 |  | | |
|  | 1.2 | Pat Ackerman | | | 9/5/2005 |  | | |
|  | 1.3 | Pat Ackerman | | | 12/20/2006 | Update Salmonella drugs to include Nalidixic acid | | |
|  | 1.4 | Pat Ackerman | | | 10/23/2007 | Added TIM, CAX, LEVO to PSMA drugs | | |
|  | 1.5 | Becky Carlson | | | 7/8/2013 | Reformatted, updated procedure | | |
|  | 2.0 | Becky Carlson | | | 10/29/2013 | Added sections for:  Pen Etest interpretation section  Deduced antibiotic resulting  CLSI CSF Reporting Rule | | |
|  | 2.1 | Becky Carlson | | | 1/16/2014 | Added *N. meningitidis* section. Amended Group A strep—perform AST only per special request; i.e. penicillin allergic. Added beta lactamase testing to *Haemophilis* section. | | |
|  | 2.2 | Becky Carlson | | | 8/6/2014 | Added *Lactobacillus* section. | | |
|  | 3.0 | Becky Carlson | | | 10/20/2016 | Revised PSMA reporting, TIM not available in U.S. Discontinued Vitek AST. | | |
|  | 4.0 | Becky Carlson | | | 11/02/2016 | Removed method for in-house performance of AST for Bacillus and *Lactobacillus*.  Removed Trimethoprim-sulfa drug reporting for *Listeria.* | | |
|  | 4.0 | Susan DeMeyere | | | 12/21/2018 | Biennial Review, fixed hyperlinks | | |
|  | 5 | Susan DeMeyere | | | 5/17/2019 | Changed KPC instructions, removed inappropriate drugs from table. | | |